Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| Check this box if no longer subject to                     | STATEMENT OF CHANGES IN BENEFICIAL | <b>OWNERSHIP</b> |
|--|------------------------------------|------------------|
| Section 16. Form 4 or Form 5 obligations may continue. See |                                    |                  |
| obligatione may continue.                                  |                                    |                  |

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Daly Richard J</u> |  |            |            |  | C.A   | 2. Issuer Name <b>and</b> Ticker or Trading Symbol  CATALYST PHARMACEUTICALS, INC.  CPRX |                            |      |   |              |  |   |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner |  |   |                    |         |
|--|--|------------|------------|--|---|--|----------------------------|------|---|--------------|--|---|--|---|--|---|--------------------|---------|
| (Last) (First) (Middle) 355 ALHAMBRA CIRCLE, SUITE 1250        |  |            |            |  |   | 3. Date of Earliest Transaction (Month/Day/Year) 12/19/2018                              |                            |      |   |              |  |   |  | Office<br>belov   | er (give title<br>v)   |   | Other (s<br>below) | specify |
| (Street) CORAL GABLES FL 33134                                 |  |            | 4. 11      | 4. If Amendment, Date of Original Filed (Month/Day/Year) |   |  |                            |      |   |              |  | 6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person |  |   |  |   |                    |         |
| (City)   | (S   | tate)      | (Zip)      |  |   |  |                            |      |   |              |  |   |  |   |  |   |                    |         |
|  |  | Tab        | le I - Non | -Deriv   | ative   | e Se   | curities                   | s Ac | quired, C   | Disp         | osed o                                     | f, or Be  | neficia                                | ly Owne   | d  |   |                    |         |
| Date   |  |            |            |  | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Yea |  | Transaction   Code (Instr. |      | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3, 4<br>5)                              |              |  | Benefic<br>Owned  | ies<br>ially<br>Following              | Form<br>(D) o   | n: Direct<br>r Indirect<br>sstr. 4)                                | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |                    |         |
|  |  |            |            |  |   |  | Code                       | v    | Amount  | (A) o<br>(D) | r Price                                    | Report<br>Transa<br>(Instr. 3   | tion(s)                                |   |  | (Instr. 4)  |                    |         |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |            |            |  |   |  |                            |      |   |              |  |   |  |   |  |   |                    |         |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)            | ive Conversion Date Execution Date, y or Exercise (Month/Day/Year) if any  |            |            | ransaction of ode (Instr. Derivative                     |   | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)                           |                            |      | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |              | 8. Price of Derivative Security (Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4)                            |  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4)                      | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |                    |         |
|  |  |            |            |  | Code  | v  | (A)                        | (D)  | Date<br>Exercisable   |              | xpiration<br>ate                           | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |   |                    |         |
| Options to<br>purchase<br>common<br>stock                      | \$2.24   | 12/19/2018 |            |  | A   |  | 25,000                     |      | 12/19/2018  | 12           | 2/19/2025                                  | Common<br>Stock   | 25,000                                 | \$0   | 265,0  | 00  | D                  |         |
| Options to<br>purchase<br>common<br>stock                      | \$2.24   | 12/19/2018 |            |  | A   |  | 25,000                     |      | 12/19/2019  | 13           | 2/19/2025                                  | Common<br>Stock   | 25,000                                 | \$0   | 290,0  | 00  | D                  |         |

**Explanation of Responses:** 

/s/ Richard Daly

12/20/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).